RxDoctor Payments Data

Kassie Hall, PA

Physician Assistant · Clifton Forge, VANPI 1023605474

Payments from drug & device makers

$2,810in general payments, 2019–2025

Across 147 payments — averaging $19.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$760
  • AstraZeneca$358
  • Lilly USA, LLC$249
  • Novo Nordisk$236
  • Otsuka America Pharmaceutical, Inc.$183
  • Astellas Pharma US Inc$140
  • plus $884 from 20 others

What the payments were for

  • Food & beverage$2,72097%
  • Education$903%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,810 in reported general payments places this provider in the 85th percentile of 3,376 physician assistant providers in Virginia.

See all physician assistant providers in Virginia

Medicare billing

Part B allowed, 2024
$59,704
Medicare patients
167
Services billed
945

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide66$86,444
EliquisApixaban54$75,900
Trelegy ElliptaFluticasone/Umeclidin/Vilanter66$50,075
JanuviaSitagliptin Phosphate34$49,394
FarxigaDapagliflozin Propanediol36$44,396
JardianceEmpagliflozin29$39,301
MounjaroTirzepatide21$22,276
TrulicityDulaglutide14$18,835
Tresiba Flextouch U-200Insulin Degludec17$18,717
Breztri AerosphereBudesonide/Glycopyr/Formoterol23$17,368
UbrelvyUbrogepant14$15,884
WegovySemaglutide11$14,821
Tresiba Flextouch U-100Insulin Degludec14$9,743
Fluticasone-SalmeterolFluticasone Propion/Salmeterol31$7,680
Lantus SolostarInsulin Glargine,hum.Rec.Anlog40$6,657

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$236$101,26577 claims
PfizerEliquis$42$75,90054 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$358$68,09080 claims
GSKTrelegy Ellipta$51$50,07566 claims
Lilly USA, LLCMounjaro, Trulicity$249$41,11135 claims
AbbVieUbrelvy$760$15,88414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,376 physician assistant providers in Virginia.

Other physician assistant in Clifton Forge

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →